Joseph Stringer
Stock Analyst at Needham
(4.87)
# 337
Out of 4,453 analysts
601
Total ratings
48.8%
Success rate
24.3%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintained: Buy | $105 | $76.52 | +37.22% | 41 | Jun 25, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $510 | $294.06 | +73.43% | 47 | Jun 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Hold | n/a | $475.20 | - | 31 | Jun 24, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $130 | $107.55 | +20.87% | 47 | Jun 15, 2026 | |
| GILD Gilead Sciences | Rated: Buy | $170 | $125.16 | +35.83% | 30 | Jun 12, 2026 | |
| STTK Shattuck Labs | Rated: Buy | $14 → $17 | $6.01 | +182.86% | 5 | Jun 8, 2026 | |
| PHAT Phathom Pharmaceuticals | Maintained: Buy | $28 | $10.61 | +163.90% | 73 | Jun 1, 2026 | |
| PLRX Pliant Therapeutics | Maintained: Hold | n/a | $1.13 | - | 33 | May 12, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $50 | $22.83 | +119.01% | 4 | May 11, 2026 | |
| STOK Stoke Therapeutics | Maintained: Buy | $40 | $30.39 | +31.62% | 44 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $5.30 | +107.55% | 34 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $9.95 | +80.90% | 46 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $110 | $53.87 | +104.20% | 40 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $46 | $60.42 | -23.97% | 42 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.22 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.35 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.27 | n/a | 13 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $23.36 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $166.06 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $53.55 | n/a | 2 | Apr 28, 2021 |
Ionis Pharmaceuticals
Jun 25, 2026
Maintained: Buy
Price Target: $105
Current: $76.52
Upside: +37.22%
Alnylam Pharmaceuticals
Jun 24, 2026
Maintained: Buy
Price Target: $510
Current: $294.06
Upside: +73.43%
Vertex Pharmaceuticals
Jun 24, 2026
Maintained: Hold
Price Target: n/a
Current: $475.20
Upside: -
Rhythm Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $130
Current: $107.55
Upside: +20.87%
Gilead Sciences
Jun 12, 2026
Rated: Buy
Price Target: $170
Current: $125.16
Upside: +35.83%
Shattuck Labs
Jun 8, 2026
Rated: Buy
Price Target: $14 → $17
Current: $6.01
Upside: +182.86%
Phathom Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $28
Current: $10.61
Upside: +163.90%
Pliant Therapeutics
May 12, 2026
Maintained: Hold
Price Target: n/a
Current: $1.13
Upside: -
BioAge Labs
May 11, 2026
Maintained: Buy
Price Target: $50
Current: $22.83
Upside: +119.01%
Stoke Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $40
Current: $30.39
Upside: +31.62%
May 8, 2026
Maintained: Buy
Price Target: $11
Current: $5.30
Upside: +107.55%
May 7, 2026
Maintained: Buy
Price Target: $18
Current: $9.95
Upside: +80.90%
May 7, 2026
Reiterated: Buy
Price Target: $110
Current: $53.87
Upside: +104.20%
May 1, 2026
Maintained: Hold
Price Target: $46
Current: $60.42
Upside: -23.97%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $2.22
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $2.35
Upside: n/a
Dec 23, 2022
Rated: Hold
Price Target: n/a
Current: $17.27
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $23.36
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $166.06
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $53.55
Upside: n/a